Earnings per share rose 24% to $3.41, compared to Wall Street's consensus estimate of $2.96, according to FactSet. Revenue for the quarter reached $11.67 billion, well above expectations of $10.91 ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Quantum computing is shaping up to be the next big investing revolution, and for a very good reason. With the power to solve ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Harvey Jones called on artificial intelligence to help him decide where to invest this year's Stocks and Shares ISA allowance ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

RBC Capital Markets analysts have expressed a cautious outlook on Smiths Group 's (LON:SMIN) stock, citing limited upside potential despite the company’s decision to pursue a partial breakup.  While ...

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...